Skip to main content
. Author manuscript; available in PMC: 2021 Nov 9.
Published in final edited form as: ACS Infect Dis. 2021 Mar 25;7(7):1969–1984. doi: 10.1021/acsinfecdis.1c00055

Table 2.

MICs for Selected Analogs against a panel of N. gonorrhoeae clinical isolates

MIC (μg/mL)
N. gonorrhoeae strains AZM 20 23 AZI
CDC 165 4 1 4 2
CDC 166 4 1 2 2
CDC 167 2 0.5 4 4
CDC 168 4 0.5 4 1
CDC 169 4 0.25 2 1
CDC 170 1 0.125 0.5 1
CDC 171 2 0.5 2 1
CDC 173 1 0.125 0.5 0.5
CDC 175 2 0.25 2 4
CDC 176 1 0.25 1 0.5
CDC 177 1 0.5 2 0.5
CDC 178 2 1 0.5 2
CDC 179 4 2 4 4
CDC 180 2 0.5 2 0.5
CDC 181 2 0.5 0.25 >64
CDC 182 4 0.5 2 1
CDC 183 2 0.25 2 1
CDC 184 2 0.25 2 1
CDC 185 4 0.5 2 1
CDC 187 2 0.25 2 4
CDC 189 2 0.06 1 0.5
CDC 190 2 0.125 1 1
CDC 197 4 2 4 2
CDC 202 4 2 4 16
CDC 211 1 2 4 1
ATCC 700825 0.5 0.5 0.5 0.25
MS11 0.5 0.125 1 0.25
WHO-K 1 0.25 1 0.25
WHO-X 1 0.25 1 0.25
WHO-W 2 0.25 1 0.125

aMIC50 2 0.5 2 2
bMIC90 4 2 4 4

AZI = azithromycin, AZM = acetazolamide.

a

MIC50: minimum inhibitory concentration at which the compound/drug inhibited 50% of the tested strains.

b

MIC90: minimum inhibitory concentration at which the compound/drug inhibited 90% of the tested strains.